PRF Technologies (PRFX) Non-Current Debt (2019 - 2020)
PRF Technologies' (PRFX) quarterly Non-Current Debt came in at $3.9 million in Q2 2020, little changed on a QoQ basis from $3.9 million in Q4 2019.
PRF Technologies (PRFX) Non-Current Debt (2019 - 2020) Analysis & Trends
PRF Technologies (PRFX) has 2 years of Non-Current Debt data on file, last reported at $3.9 million in Q2 2020.
- Quarterly Non-Current Debt changed N/A year-over-year to $3.9 million in Q2 2020, while the trailing twelve-month figure through Jun 2020 was $3.9 million (changed N/A YoY) and the FY2019 annual result came in at $3.9 million, changed N/A from the prior year.
- Non-Current Debt steadied at $3.9 million in Q2 2020, from $3.9 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $3.9 million in Q4 2019 to a low of $3.9 million in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -8.44 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 12.09 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 27.73 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 11.61 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 3.85 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 130.00 Mn |
| 10 | PRF Technologies | 654,452.72 | -3.49 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2020 | 3.93 Mn |
| Dec 31, 2019 | 3.93 Mn |